Filtered By:
Specialty: Cardiology
Drug: Aspirin
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 932 results found since Jan 2013.
Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularisation
CONCLUSIONS: In unselected patients undergoing revascularisation for peripheral arterial disease, the majority presents with characteristics that, at present, preclude prescription of rivaroxaban in addition to aspirin. This patient cohort represents a population with higher rates of comorbidities and more complex vascular interventions, but might also benefit from dual pathway inhibition strategy.PMID:34913631 | DOI:10.23736/S0392-9590.21.04816-1
Source: International Angiology - December 16, 2021 Category: Cardiology Authors: Maria A Moll Daniela Zwerger Kristina J Grassl Werner Westreicher Sabrina B Neururer Clemens Wi Moll Sabine H Wipper Josef Klocker Source Type: research
Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis
Conclusions: Current cigarette smoking, diabetes mellitus, and hypertension are independently associated with incident ASCVD over 16-year follow-up among those with CAC=0. Family history of premature ASCVD may be associated with ASCVD risk among women only.PMID:34879218 | DOI:10.1161/CIRCULATIONAHA.121.056705
Source: Atherosclerosis - December 8, 2021 Category: Cardiology Authors: Mahmoud Al Rifai Michael J Blaha Vijay Nambi Steven J C Shea Erin D Michos Roger S Blumenthal Christie M Ballantyne Moyses Szklo Philip Greenland Michael D Miedema Khurram Nasir Jerome I Rotter Xiuqing Guo Jie Yao Wendy S Post Salim S Virani Source Type: research
Aspirin in the Modern Era of Cardiovascular Disease Prevention
Methodist Debakey Cardiovasc J. 2021 Sep 24;17(4):36-47. doi: 10.14797/mdcvj.293. eCollection 2021.ABSTRACTAspirin's antithrombotic effects have a long-established place in the prevention of cardiovascular disease (CVD), and its traditional use as a core therapy for secondary prevention of CVD is well recognized. However, with the advent of newer antiplatelet agents and an increasing understanding of aspirin's bleeding risks, its role across the full spectrum of modern CVD prevention has become less certain. As a consequence, recent trials have begun investigating aspirin-free strategies in secondary prevention. For exampl...
Source: Methodist DeBakey Cardiovascular Journal - November 26, 2021 Category: Cardiology Authors: Ella Murphy James M G Curneen John W McEvoy Source Type: research
